iShares Nasdaq Biotechnology ETF
Open Ended Investment Company domiciled in United States
Key Information
Legal Documents
Performance
Analysis

Fund Profile

Category: Open Ended Investment Company

The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Risk and reward profile
6
Lower Risk
Possible Lower
Returns
Higher Risk
Possible Higher
Returns
Key Information
Closing Price 25/09/2020133.47
Morningstar category-
CurrencyUSD
Distribution statusDistributing
ISINUS4642875565
Inception Date05/02/2001
Minimum initial amount-
Exchange NameNASDAQ
TickerIBB
Fees And Charges
Custody feeNone
Ongoing charge-% of which none is paid to MeDirect
Fund management company
AddressiShares iShares 400 Howard Street USA San Francisco 94105 United States
Manager NameGreg Savage
Manager Start Date01/01/2008
Websitewww.ishares.com
Total Net Assets (mil)- (31/08/2020)
UCITSNo
Administrator-

Documents

Prospectus
en 17/08/2020
Annual Report
en 31/03/2020
Semi Annual Report
en 30/09/2019
Morningstar Report
27/09/2020

Performance

Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
The performance in euro can be lower or higher than the performance in the currency of denomination of the fund due to fluctuations in exchange rates.
Annualised performance in USD
PeriodAnnualised returnDate
1 year31.01%25/09/2020
3 years6.76%25/09/2020
5 years5.46%25/09/2020
10 years16.70%25/09/2020
Since launch7.49%25/09/2020
Cumulative performance in USD
Performance
YTD 01/01/202010.98
1 month0.36
3 months-3.18
6 months31.04
Quarterly Returns
Q 1Q 2Q 3Q 4
2020-10.55%26.99%--
201915.94%-2.34%-8.74%21.17%
2018-0.03%3.03%11.07%-20.92%
201710.62%5.79%7.62%-3.87%
2016-22.87%-1.27%12.51%-8.29%
Dividend
Date ex dividendGross dividendPayment Date
25/03/20200.0631/03/2020
17/06/20190.0821/06/2019
26/06/20180.1602/07/2018
24/03/20170.1030/03/2017
23/03/20160.0530/03/2016
24/06/20150.0230/06/2015
25/06/20140.1301/07/2014
27/06/20130.0203/07/2013
23/03/20120.0129/03/2012
22/12/20110.0029/12/2011
24/09/20100.1730/09/2010
24/06/20080.0630/06/2008
29/06/20070.0306/07/2007

Asset Allocation
% Long% Short% Net Assets
Stock99.84%0.00%99.84%
Bond0.00%0.00%0.00%
Cash0.16%0.00%0.16%
Other0.00%0.00%0.00%
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
23.0922.4023.75
Sharpe Ratio
1.280.340.23
Sortino Ratio
3.380.550.32
Positive Months8.0020.0035.00
Negative Months4.0016.0025.00
Worst Month-5.62-14.62-21.02
World Regions
Region%
United States91.62
Asia - Emerging2.99
Eurozone2.62
United Kingdom1.24
Europe - ex Euro0.83
Asia - Developed0.21
Canada0.19
Middle East0.14
Stock Sector Weighting
Sector% of Equity
Healthcare99.78
Basic Materials0.06
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Large
Size
Mid
Small
Value
Blend
Growth
Style
$
133.47
Closing Price
All key information and documents must be reviewed before being able to Invest.